Detalles de la búsqueda
1.
Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
Breast Cancer Res
; 24(1): 74, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36320066
2.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31753727
3.
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Invest New Drugs
; 35(3): 334-344, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28299514
4.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Invest New Drugs
; 34(5): 625-35, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27350064
5.
Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).
Histopathology
; 65(6): 879-96, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25039923
6.
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study.
J Gastric Cancer
; 23(2): 289-302, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37129153
7.
Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer.
Appl Immunohistochem Mol Morphol
; 30(8): 577-583, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35880975
8.
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
JTO Clin Res Rep
; 3(4): 100303, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35369607
9.
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Clin Cancer Res
; 28(8): 1500-1506, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35121623
10.
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Clin Lung Cancer
; 23(4): 300-310, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35400584
11.
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization.
Arch Pathol Lab Med
; 146(3): 351-359, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232984
12.
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.
Nat Commun
; 13(1): 1878, 2022 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35388003
13.
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Clin Cancer Res
; 27(19): 5258-5271, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301751
14.
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Clin Cancer Res
; 27(4): 992-1002, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33046516
15.
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.
JTO Clin Res Rep
; 2(6): 100171, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34590023
16.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Curr Med Res Opin
; 37(10): 1769-1778, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34229554
17.
Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.
Magn Reson Med
; 63(4): 940-50, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20373395
18.
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
J Thorac Oncol
; 15(1): 80-90, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31622732
19.
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Clin Cancer Res
; 26(3): 566-580, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31615937
20.
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Front Oncol
; 10: 578756, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33194700